16.92

3.93% 0.64

After Hours: 16.88 -0.04 -0.24%

Neuropace Inc (NPCE)

Overview News Price History Financials Discussions Forecast

Neuropace Inc stock is traded at $16.92, with a volume of 172.54K. It is up +3.93% in the last 24 hours and down -0.35% over the past month. NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Previous Close:

$16.28

Open:

$16.38

24h Volume:

172.54K

Relative Volume:

0.83

Market Cap:

$576.87M

Revenue:

$99.99M

Net Income/Loss:

$-21.47M

P/E Ratio:

-25.65

EPS:

-0.6597

Net Cash Flow:

$-11.34M

1W Performance:

+10.16%

1M Performance:

-0.35%

6M Performance:

+17.91%

1Y Performance:

-5.32%

1-Day Range:

$16.38

$17.10

1-Week Range:

$15.37

$17.10

52-Week Range:

$7.5625

$19.60

Neuropace Inc Stock (NPCE) Company Profile

Name

Neuropace Inc

Sector

Healthcare (1108)

Industry

Medical Devices (143)

Phone

(650) 237-2700

Address

455 N. BERNARDO AVENUE, MOUNTAIN VIEW

Employee

220

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

NPCE's Discussions on Twitter

Compare NPCE vs ABT, SYK, MDT, BSX, EW

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NPCE Neuropace Inc	16.92	555.05M	99.99M	-21.47M	-11.34M	-0.6597
ABT Abbott Laboratories	87.41	152.88B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	316.48	120.18B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	78.60	100.34B	35.48B	4.64B	5.41B	3.582
BSX Boston Scientific Corp	57.78	84.95B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	85.78	47.91B	6.30B	1.07B	1.09B	1.8406

Neuropace Inc Stock (NPCE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-28-25	Initiated	H.C. Wainwright	Buy
Jan-21-25	Initiated	UBS	Buy
Mar-14-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Jan-30-24	Initiated	Leerink Partners	Outperform
Nov-10-23	Initiated	Cantor Fitzgerald	Overweight
Aug-24-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Feb-22-23	Initiated	Lake Street	Buy
Apr-06-22	Initiated	Wolfe Research	Outperform
Jan-19-22	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-07-22	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Nov-11-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Aug-18-21	Initiated	Robert W. Baird	Outperform
May-17-21	Initiated	JP Morgan	Overweight
May-17-21	Initiated	Morgan Stanley	Overweight
May-17-21	Initiated	SVB Leerink	Outperform
May-17-21	Initiated	Wells Fargo	Overweight

View All

Neuropace Inc Stock (NPCE) Latest News

May 25, 2026

NeuroPace (NPCE) CFO receives RSU and stock option awards in Form 4 filing - Stock Titan

May 19, 2026

NeuroPace (NPCE) CMO receives new RSU and stock option awards - Stock Titan

May 19, 2026

NeuroPace (NPCE) CEO receives new RSU and stock option awards - Stock Titan

May 19, 2026

May 18, 2026

Here's why you should add NeuroPace stock to your portfolio now - MSN

May 18, 2026

H.C. Wainwright raises NeuroPace stock price target to $20 on guidance - Investing.com Australia

May 18, 2026

May 15, 2026

NPCE Maintains by HC Wainwright & Co. -- Price Target Raised to $20 - GuruFocus

May 15, 2026

First Light, Mathew Arens report ~2.9M NPCE shares (NPCE) - Stock Titan

May 15, 2026

OrbiMed reports 2,096,527 shares (6.2%) in NeuroPace (NPCE) - Stock Titan

May 15, 2026

H.C. Wainwright Maintains NeuroPace(NPCE.US) With Buy Rating, Raises Target Price to $20 - Moomoo

May 15, 2026

Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $19 - Moomoo

May 15, 2026

NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st

May 15, 2026

May 14, 2026

(NPCE) Movement as an Input in Quant Signal Sets - Stock Traders Daily

May 14, 2026

NeuroPace, Inc. (NASDAQ:NPCE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

May 14, 2026